Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Adagene (Nasdaq: ADAG) has partnered with ConjugateBio to develop novel bispecific Antibody Drug Conjugates (ADCs). Under the agreement, Adagene will provide a proprietary antibody for ConjugateBio's ADC development programs, receiving an undisclosed upfront payment plus milestone and royalty payments while retaining all non-ADC rights.
The collaboration aims to leverage Adagene's antibody discovery capabilities and ConjugateBio's ADC development expertise in a market expected to reach over $30 billion by 2030. The partnership builds on Adagene's track record with ADG126, demonstrating their ability to create safe and efficacious molecules.
Adagene (Nasdaq: ADAG) ha stretto una collaborazione con ConjugateBio per sviluppare nuovi Anticorpi Coniugati Bispecifici (ADC). Secondo l'accordo, Adagene fornirà un anticorpo proprietario per i programmi di sviluppo ADC di ConjugateBio, ricevendo un pagamento iniziale riservato, oltre a pagamenti legati a traguardi e royalty, mantenendo tutti i diritti non relativi agli ADC.
La collaborazione mira a sfruttare le capacità di scoperta anticorpale di Adagene e l’expertise nello sviluppo di ADC di ConjugateBio, in un mercato previsto superare i 30 miliardi di dollari entro il 2030. La partnership si basa sul successo di Adagene con ADG126, dimostrando la loro competenza nella creazione di molecole sicure ed efficaci.
Adagene (Nasdaq: ADAG) se ha asociado con ConjugateBio para desarrollar nuevos anticuerpos conjugados bispecíficos (ADC). Según el acuerdo, Adagene proporcionará un anticuerpo propietario para los programas de desarrollo de ADC de ConjugateBio, recibiendo un pago inicial confidencial, además de pagos por hitos y regalías, manteniendo todos los derechos no relacionados con ADC.
La colaboración busca aprovechar las capacidades de descubrimiento de anticuerpos de Adagene y la experiencia en desarrollo de ADC de ConjugateBio, en un mercado que se espera supere los 30 mil millones de dólares para 2030. La asociación se basa en el historial de Adagene con ADG126, demostrando su capacidad para crear moléculas seguras y eficaces.
Adagene (나스닥: ADAG)는 ConjugateBio와 협력하여 새로운 이중특이성 항체 약물 접합체(ADC)를 개발합니다. 이 계약에 따라 Adagene는 ConjugateBio의 ADC 개발 프로그램에 독점 항체를 제공하며, 비공개 선급금과 마일스톤 및 로열티 지급을 받는 동시에 ADC와 관련 없는 모든 권리를 유지합니다.
이번 협력은 Adagene의 항체 발굴 역량과 ConjugateBio의 ADC 개발 전문성을 결합하여 2030년까지 300억 달러 이상으로 예상되는 시장을 공략하는 것을 목표로 합니다. 이 파트너십은 ADG126을 통한 Adagene의 성공 사례를 바탕으로 안전하고 효과적인 분자 개발 능력을 입증합니다.
Adagene (Nasdaq : ADAG) s'est associé à ConjugateBio pour développer de nouveaux conjugués anticorps-médicaments bispécifiques (ADC). Dans le cadre de cet accord, Adagene fournira un anticorps propriétaire pour les programmes de développement ADC de ConjugateBio, recevant un paiement initial confidentiel ainsi que des paiements liés à des jalons et des redevances, tout en conservant tous les droits non liés aux ADC.
Cette collaboration vise à tirer parti des capacités de découverte d’anticorps d’Adagene et de l’expertise en développement d’ADC de ConjugateBio, sur un marché attendu à dépasser 30 milliards de dollars d’ici 2030. Ce partenariat s’appuie sur le succès d’Adagene avec ADG126, démontrant leur aptitude à créer des molécules sûres et efficaces.
Adagene (Nasdaq: ADAG) hat eine Partnerschaft mit ConjugateBio geschlossen, um neuartige bispezifische Antikörper-Wirkstoff-Konjugate (ADCs) zu entwickeln. Im Rahmen der Vereinbarung wird Adagene einen proprietären Antikörper für die ADC-Entwicklungsprogramme von ConjugateBio bereitstellen und erhält eine nicht offengelegte Vorauszahlung sowie Meilenstein- und Lizenzgebühren, während alle nicht-ADC-Rechte behalten werden.
Die Zusammenarbeit zielt darauf ab, Adagenes Antikörper-Entdeckungsfähigkeiten und ConjugateBios ADC-Entwicklungsexpertise in einem Markt zu nutzen, der voraussichtlich bis 2030 über 30 Milliarden US-Dollar erreichen wird. Die Partnerschaft baut auf Adagenes Erfolgen mit ADG126 auf und zeigt deren Fähigkeit, sichere und wirksame Moleküle zu entwickeln.
- Partnership targets ADC market projected to reach over $30 billion by 2030
- Company will receive upfront payment plus milestone and royalty payments
- Adagene retains all non-ADC rights to the partnered antibody
- Leverages existing success with ADG126 platform
- Financial terms and upfront payment amount not disclosed
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs
SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies’ bispecific ADC development programs.
“We have been very impressed with ConjugateBio’s ability to streamline ADC development, and we are pleased to provide an internally developed antibody for this purpose. By combining this antibody with various payloads, ConjugateBio is advancing the ADC landscape, which is expected to reach over
Kum Yoo, Co-founder and CEO of ConjugateBio added, “Adagene’s exemplary and differentiated antibody discovery capabilities give us confidence that in our hands, we can develop novel, potent and safe antibody drug conjugates. Based on what we’ve seen with ADG126, Adagene excels in pushing the boundaries of what is possible when it comes to creating safe, well tolerated and efficacious molecules.”
Under the terms of the agreement, Adagene will receive an undisclosed upfront payment, as well as milestone and royalty payments. Adagene retains all non-ADC rights to this partnered antibody.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
About ConjugateBio
ConjugateBio is a privately held, venture-backed biotechnology company based in Princeton, NJ, focused on developing first-in-class bispecific antibody-drug conjugates (ADCs) against solid tumors. The company is building a pipeline of innovative therapeutics targeting cancers across a broad spectrum of indications leveraging third generation linker-payloads with potential best-in-class profile.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
ConjugateBio Contact:
Kum Yoo, MD
Kum.yoo@conjugatebio.com
FAQ
What is the partnership between Adagene (ADAG) and ConjugateBio?
What is the market potential for ADCs according to Adagene (ADAG)?
What rights does Adagene (ADAG) retain in the ConjugateBio partnership?
What are the financial terms of Adagene's (ADAG) partnership with ConjugateBio?
Why did ConjugateBio choose to partner with Adagene (ADAG)?
